Mangrove Partners IM LLC Takes Position in Pfizer Inc. $PFE

Mangrove Partners IM LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 33,105 shares of the biopharmaceutical company’s stock, valued at approximately $844,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer during the third quarter worth $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter valued at about $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter worth about $32,000. Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer during the 2nd quarter worth about $33,000. Finally, True Wealth Design LLC raised its position in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.0%

Shares of Pfizer stock opened at $26.60 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock’s 50 day simple moving average is $26.50 and its 200-day simple moving average is $25.52. The stock has a market cap of $151.23 billion, a P/E ratio of 19.56 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. BMO Capital Markets restated an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Monday. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Finally, Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.